| Clinical factors affecting serum potassium concentration in cardio-renal decompensation syndrome. | |
| | |
MedLine Citation:
|
PMID: 18804879 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Renin-angiotensin-aldosterone system (RAAS) inhibitors are currently indispensable for the treatment of heart failure. It is well known that hyperkalemia is likely to occur in renal failure; however, it has not yet been clarified how the serum potassium concentration changes as heart failure progresses. Currently, the cardio-renal decompensation syndrome holds that the serum potassium concentration is altered similarly by both heart failure and renal failure; however, there are no definitive reports on this. In order to use RAAS inhibitors more safely and effectively in heart failure, it is necessary to understand the factors affecting serum potassium concentration in the clinical setting. METHODS AND RESULTS: We examined the clinical factors affecting serum potassium concentration in 1035 consecutive patients with cardiovascular disease who were hospitalized in our institution. Multiple regression analysis showed that the independent factors associated with an elevated serum potassium concentration were renal insufficiency evaluated by estimated glomerular filtration rate (eGFR) (P<0.0001), diabetes mellitus evaluated by HbA(1c) (P=0.0005) and the use of RAAS inhibitors (P=0.0010). The independent factors associated with a decreased serum potassium concentration were mean blood pressure (P<0.0001), heart failure evaluated by log BNP (P=0.0164) and the use of diuretics (P=0.0232). CONCLUSIONS: The serum potassium concentration decreases with the severity of heart failure if renal function is preserved. From the perspective of potassium homeostasis, we could use the RAAS inhibitors more aggressively in patients with heart failure who do not have renal failure. |
| | |
Authors:
|
Hirofumi Ueno; Michihiro Yoshimura; Masafumi Nakayama; Megumi Yamamuro; Tsunenori Nishijima; Kenichi Kusuhara; Yasuhiro Nagayoshi; Sunao Kojima; Koichi Kaikita; Hitoshi Sumida; Seigo Sugiyama; Hisao Ogawa |
Related Documents
:
|
2800999 - Heart-transplant and mono-amine oxidase inhibitors. 2956399 - Returning to work after heart transplantation. 7608449 - Coronary artery response to cold-pressor test is impaired early after operation in hear... 15776689 - Selection of congestive heart failure patients for heart transplant. 15910289 - A single solution for multiple organ procurement and preservation. 8049339 - Computer-assisted neurovegetative monitoring in patients after heart transplantation. 240079 - Transplantation models using the regional lymph node. 12401859 - Interstitial expression of alpha-sma: an early marker of chronic renal allograft dysfun... 22244709 - A comparative study of chronic kidney disease in dogs and cats: induction of cyclooxyge... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't Date: 2008-09-19 |
Journal Detail:
|
Title: International journal of cardiology Volume: 138 ISSN: 1874-1754 ISO Abbreviation: Int. J. Cardiol. Publication Date: 2010 Jan |
Date Detail:
|
Created Date: 2010-02-01 Completed Date: 2010-04-13 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8200291 Medline TA: Int J Cardiol Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 174-81 Citation Subset: IM |
Copyright Information:
|
Copyright (c) 2008 Elsevier Ireland Ltd. All rights reserved. |
Affiliation:
|
Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto 860-8556, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Aged, 80 and over Angiotensin II Type 1 Receptor Blockers / therapeutic use Angiotensin-Converting Enzyme Inhibitors / therapeutic use* Child Disease Progression Diuretics / therapeutic use* Female Glomerular Filtration Rate / physiology Heart Failure* / blood, complications, drug therapy Humans Hyperkalemia* / blood, complications, drug therapy Kidney Failure* / blood, complications, drug therapy Male Middle Aged Natriuretic Peptide, Brain / blood Potassium / blood* Regression Analysis Renin-Angiotensin System / drug effects, physiology Severity of Illness Index Spironolactone / therapeutic use* Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Diuretics; 114471-18-0/Natriuretic Peptide, Brain; 52-01-7/Spironolactone; 7440-09-7/Potassium |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Differential impact of metabolic syndrome on arterial stiffness and wave reflections: Focus on disti...
Next Document: Magnetic resonance reveals long-term sequelae of apical ballooning syndrome.